Endovasc Ltd, Inc. - a biotechnology firm with two cardiovascular drugs approved for FDA Phase III trials, announced today that it has signed a Letter of Intent with XM International d/b/a Basic Research, Inc. to start a stem cell recruitment study using Angiogenix(TM) for accelerating muscle tissue rebuilding after long term disability.
Before Metabolic Research, Inc. (the company that makes Stemulite), Dr. Summers founded a company called Endovasc.
Market Data 
Markets 
AI
